Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF
January 17 2020 - 1:00AM
Business Wire
Regulatory News:
Under the liquidity agreement entrusted by IPSEN to NATIXIS ODDO
BHF, as of December 31, 2019, the following resources were included
to the dedicated liquidity account:
- 29,068 shares - €1,619,779.77
It is reminded that as of the date of the signature of the
agreement, the following assets were allocated to the liquidity
account:
- 12,751 shares - €3,137,934.80
Between July 1, 2019 and December 31, 2019 have been
executed:
- 1,955 purchase transactions - 1,691 sell transactions
Under the same period, the volumes traded represented:
- 280,223 shares and €26,511,203.80 to the purchase - 255,638
shares and €23,923,684.55 to the sell
About Ipsen Ipsen is a global specialty-driven
biopharmaceutical group focused on innovation and Specialty Care.
The group develops and commercializes innovative medicines in three
key therapeutic areas - Oncology, Neuroscience and Rare Diseases.
Its commitment to Oncology is exemplified through its growing
portfolio of key therapies for prostate cancer, neuroendocrine
tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has
a well-established Consumer Healthcare business. With total sales
over €2.2billion in 2018, Ipsen sells more than 20 drugs in over
115 countries, with a direct commercial presence in more than 30
countries. Ipsen's R&D is focused on its innovative and
differentiated technological platforms located in the heart of the
leading biotechnological and life sciences hubs (Paris-Saclay,
France; Oxford, UK; Cambridge, US). The Group has about 5,700
employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and
in the United States through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information on
Ipsen, visit www.ipsen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200116005644/en/
Media Christian Marcoux Senior Vice President,
Global Communications +33 (0)1 58 33 67 94
christian.marcoux@ipsen.com
Fanny Allaire Director, Ipsen France Hub, Global
Communications +33 (0) 1 58 33 58 96 fanny.allaire@ipsen.com
Financial Community Eugenia Litz Vice President,
Investor Relations +44 (0) 1753 627721 eugenia.litz@ipsen.com
Myriam Koutchinsky Investor Relations Manager +33 (0)1 58
33 51 04 myriam.koutchinsky@ipsen.com
Ipsen (EU:IPN)
Historical Stock Chart
From Apr 2024 to May 2024
Ipsen (EU:IPN)
Historical Stock Chart
From May 2023 to May 2024